Skip to content
Men Under Microscope – Lifestyle
Home
Sample Page
Author:
Rezolute, Inc.
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
June 4, 2026
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
June 2, 2026
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
May 12, 2026
Rezolute to Participate in Upcoming Investor Conferences
May 11, 2026
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
May 1, 2026
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
April 21, 2026
Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
March 24, 2026